Project Grant K08CA293160
Award Date
7/2/25
Completion Date
6/30/30
Dollars Obligated
$210K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $301,263 to the University of Illinois to conduct research on the relationship between diet, gut microbiome, and cancer treatment-related cognitive impairment (CRCI) in breast cancer survivors (BCS). The key objectives are: Determine how adherence to a Mediterranean diet and gut microbiome relate to cognitive function in 30 BCS before, during, and after chemotherapy. Develop a...
This federal Project Grant award for $538,553, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will support research to define the role of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The 5-year project, which commenced on April 1, 2025, will be conducted by the University...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $553,605.63 to Rutgers, The State University of New Jersey to investigate the role of mitochondrial dysfunction in driving aggressive prostate cancer, particularly in high-risk populations such as African American men. The award aims to: Identify mitochondrial DNA (mtDNA) alterations in prostate cancer mouse models and assess their clinical relevance for prostate cancer disparities....
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $182,236 to New York University School of Medicine to adapt and pilot test an evidence-based sexual health communication skills training intervention for prostate cancer patients. The key products and services to be delivered include: Conducting focus groups with prostate cancer patients and interviews with providers to identify barriers and facilitators to patient-provider communication...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,317 to the Icahn School of Medicine at Mount Sinai to conduct research on the tumor microenvironment and mechanisms driving prostate cancer progression to metastatic castration-resistant disease. The research aims to: Determine how epithelial-mesenchymal transition (EMT) and mesenchymal-epithelial transition (MET) signaling within the tumor microenvironment impact anoikis...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This federal Project Grant award of $1,330,736, provided by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to improve weight management outcomes among Black American women with obesity. The award will fund a 6-month randomized controlled trial comparing a Mediterranean diet-based weight loss intervention (MEDDIET-WL) to the same intervention enhanced with training participants as "change agents" to share...
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $327,496 to the University of Missouri System to design and develop implementation interventions aimed at improving the quality of active surveillance for men with favorable-risk prostate cancer. The project, awarded on September 13, 2024, seeks to: 1) assess key implementation determinants, 2) design and tailor interventions to support quality...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research aimed at overcoming resistance to radiopharmaceutical therapy (RPT) in prostate cancer. The $404,972 award, effective August 1, 2025 through July 31, 2027, will enable researchers at the University of California, Los Angeles (UCLA) to investigate how the tumor microenvironment, specifically the enzyme ENPP1, can limit the immune-activating effects of PSMA-targeted RPT....